Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, et al. Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN. Am Heart J 2024 May 3:S0002-8703(24)00116-9. doi: 10.1016/j.ahj.2024.
PMID: 38705341